PRIDE. Assessment of the Efficacy, Adherence and Tolerability of the Single Pill Combination Bisoprolol/Perindopril
該当なし
完了
NCT04656847
| 対象疾患 | Coronary Artery Disease, Myocardial Infarction, Arterial Hypertension |
|---|
| 相 | 該当なし |
|---|
| スポンサー | Servier Russia |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 504 名 |
|---|
| 介入（薬剤） | in daily everyday routine practice |
|---|
| 開始日 | 2021年3月1日 |
|---|
| 完了日 | 2021年10月5日 |
|---|
| 結果公開日 | 2024年11月1日 |
|---|
概要
This non-interventional, ambispective study was aimed at evaluating the effectiveness, safety, and tolerability of bisoprolol and perindopril SPC in previous myocardial infarction patients with HTN and CAD treated with the drug for 12 weeks in the daily clinical practice. SPC will be used according to the approved instruction for medical use of the medicine. This is a multi-centre, observational, incomparative, ambispective study, which will retrospectively and prospectively collect clinical variables and socio-demographic data from medical records of patients with HTN and previous MI initiated with bisoprolol/perindopril SPC in real life settings.
Antihypertensive Effectiveness (SBP and DBP) of Bisoprolol/Perindopril SPC in CAD Patients With Previous MI and HTN at Week 12 of Treatment Compared With Baseline
3 months · mm Hg
| CAD Patients With Previous MI and HTN | -24.92 ± 16.43 mm Hg |
|---|
| CAD Patients With Previous MI and HTN | -12.21 ± 11.03 mm Hg |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。